Healthcare provider profile · identity verified

Ismael Bague, M.D.

Allopathic & Osteopathic Physicians|Family Medicine · ARECIBO, PR · NPI 1386603041

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Ismael Bague, M.D. received $100.68 in general payments during 2025 across 2 reported records.

AstraZeneca Pharmaceuticals LP accounted for 76.9% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Paxlovid.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Brilinta by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Farxiga by this doctor in 2024.

PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Eliquis by this doctor in 2024.

PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$100.68

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$77.44	76.9%	1	2025
PFIZER INC.	Unresolved — no canonical attribution shown	$23.24	23.1%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$100.68	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
AIRSUPRA Normalized: airsupra	Drug	AstraZeneca Pharmaceuticals LP	$77.44	1	2025
Source payment records 2025-10-09 · AstraZeneca Pharmaceuticals LP · $77.44 · Open Payments source
PAXLOVID Normalized: paxlovid	Drug	PFIZER INC.	$23.24	1	2025
Source payment records 2025-03-26 · PFIZER INC. · $23.24 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
PAXLOVID paxlovid	2025	Paxlovid	2024	18	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	BRILINTA open payments reported associated product	CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430	Brilinta · 2024 Exact normalized brand match · 1 Part D row	24	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	162	23
PFIZER INC. Exact reporting entity; no affiliate inference	2025	ELIQUIS open payments reported associated product	CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063	Eliquis · 2024 Exact normalized brand match · 1 Part D row	119	16
PFIZER INC. Exact reporting entity; no affiliate inference	2025	PAXLOVID open payments reported associated product	CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432	Paxlovid · 2024 Exact normalized brand match · 1 Part D row	18	18

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Losartan Potassium	Losartan Potassium	972	158
Famotidine	Famotidine	915	158
Gabapentin	Gabapentin	819	133
Synthroid	Levothyroxine Sodium	796	135
Simvastatin	Simvastatin	780	135
Atorvastatin Calcium	Atorvastatin Calcium	719	127
Hydrochlorothiazide	Hydrochlorothiazide	618	104
Sertraline Hcl	Sertraline Hcl	616	94
Amlodipine Besylate	Amlodipine Besylate	601	96
Metformin Hcl	Metformin Hcl	599	96
Omeprazole	Omeprazole	569	91
Metoprolol Succinate	Metoprolol Succinate	446	72
Donepezil Hcl	Donepezil Hcl	417	56
Diclofenac Potassium	Diclofenac Potassium	387	129
Glimepiride	Glimepiride	382	65
Rosuvastatin Calcium	Rosuvastatin Calcium	379	71
Ezetimibe	Ezetimibe	369	62
Tamsulosin Hcl	Tamsulosin Hcl	355	66
Trazodone Hcl	Trazodone Hcl	325	60
Lisinopril	Lisinopril	316	63
Furosemide	Furosemide	313	58
Temazepam	Temazepam	292	58
Lantus	Insulin Glargine,hum.Rec.Anlog	280	47
Memantine Hcl	Memantine Hcl	261	42
Spironolactone	Spironolactone	256	39
Clonazepam	Clonazepam	244	42
Betamethasone Valerate	Betamethasone Valerate	232	89
Quetiapine Fumarate	Quetiapine Fumarate	226	34
Clopidogrel	Clopidogrel Bisulfate	207	29
Pantoprazole Sodium	Pantoprazole Sodium	206	39
Atenolol	Atenolol	180	35
Irbesartan	Irbesartan	168	26
Carvedilol	Carvedilol	162	26
Farxiga	Dapagliflozin Propanediol	162	23
Baclofen	Baclofen	152	49
Finasteride	Finasteride	151	25
Montelukast Sodium	Montelukast Sodium	149	35
Glipizide	Glipizide	145	19
Levetiracetam	Levetiracetam	134	20
Mupirocin	Mupirocin	131	69
Levothyroxine Sodium	Levothyroxine Sodium	130	28
Metoprolol Tartrate	Metoprolol Tartrate	128	19
Buspirone Hcl	Buspirone Hcl	127	27
Pentoxifylline	Pentoxifylline	124	15
Enalapril Maleate	Enalapril Maleate	120	18
Eliquis	Apixaban	119	16
Janumet	Sitagliptin Phos/Metformin Hcl	119	21
Fenofibrate	Fenofibrate Nanocrystallized	115	21
Lactulose	Lactulose	115	28
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	115	24
Sucralfate	Sucralfate	109	35
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	101	45
Fluticasone Propionate	Fluticasone Propionate	91	30
Lorazepam	Lorazepam	88	15
Paroxetine Hcl	Paroxetine Hcl	88	18
Oxybutynin Chloride Er	Oxybutynin Chloride	87	17
Isosorbide Mononitrate Er	Isosorbide Mononitrate	81	15
Albuterol Sulfate Hfa	Albuterol Sulfate	77	19
Methotrexate	Methotrexate Sodium	76	13
Fluoxetine Hcl	Fluoxetine Hcl	75	13
Nabumetone	Nabumetone	75	18
Etodolac	Etodolac	74	22
Mirtazapine	Mirtazapine	72	12
Haloperidol	Haloperidol	68	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	68	58
Alendronate Sodium	Alendronate Sodium	66	13
Clobetasol Propionate	Clobetasol Propionate	63	18
Glipizide Er	Glipizide	63	suppressed
Azithromycin	Azithromycin	61	46
Carbidopa-Levodopa	Carbidopa/Levodopa	61	suppressed
Cilostazol	Cilostazol	61	16
Pioglitazone Hcl	Pioglitazone Hcl	61	11
Citalopram Hbr	Citalopram Hydrobromide	60	11
Sulindac	Sulindac	59	25
Ciprofloxacin Hcl	Ciprofloxacin Hcl	52	45
Verapamil Er	Verapamil Hcl	51	suppressed
Galantamine Hbr	Galantamine Hbr	50	suppressed
Latanoprost	Latanoprost	50	suppressed
Methylprednisolone	Methylprednisolone	50	37
Humalog	Insulin Lispro	49	suppressed
Ibuprofen	Ibuprofen	49	24
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	48	suppressed
Divalproex Sodium	Divalproex Sodium	48	suppressed
Hydralazine Hcl	Hydralazine Hcl	47	suppressed
Trijardy Xr	Empaglifloz/Linaglip/Metformin	47	suppressed
Naproxen	Naproxen	46	16
Colchicine	Colchicine	45	12
Terbinafine Hcl	Terbinafine Hcl	45	29
Meloxicam	Meloxicam	44	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	44	suppressed
Meclizine Hcl	Meclizine Hcl	43	16
Sure Comfort	Syringe And Needle,insulin,1ml	42	suppressed
Neomycin-Polymyxin-Hc	Neomycin/Polymyxin B/Hydrocort	41	29
Pravastatin Sodium	Pravastatin Sodium	41	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	40	suppressed
Hydrocortisone	Hydrocortisone	40	15
Olanzapine	Olanzapine	40	suppressed
Rivastigmine	Rivastigmine	40	suppressed
Diclofenac Sodium Er	Diclofenac Sodium	39	11
Galantamine Er	Galantamine Hbr	38	suppressed
Nifedipine Er	Nifedipine	38	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	35	21
Ketorolac Tromethamine	Ketorolac Tromethamine	35	30
Levofloxacin	Levofloxacin	35	27
Naproxen Sodium	Naproxen Sodium	35	16
Tramadol Hcl	Tramadol Hcl	35	23
Diclofenac Sodium	Diclofenac Sodium	34	suppressed
Duloxetine Hcl	Duloxetine Hcl	34	suppressed
Jardiance	Empagliflozin	34	suppressed
Valsartan	Valsartan	34	suppressed
Carbamazepine	Carbamazepine	33	suppressed
Dexamethasone	Dexamethasone	33	28
Albuterol Sulfate	Albuterol Sulfate	32	29
Enulose	Lactulose	32	suppressed
Humulin R	Insulin Regular, Human	32	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	32	suppressed
Xarelto	Rivaroxaban	32	suppressed
Xigduo Xr	Dapaglifloz Propaned/Metformin	32	suppressed
Alprazolam	Alprazolam	31	suppressed
Prednisone	Prednisone	31	15
Sildenafil Citrate	Sildenafil Citrate	31	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	31	24
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	31	suppressed
Testosterone Cypionate	Testosterone Cypionate	29	suppressed
Amiodarone Hcl	Amiodarone Hcl	27	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	27	24
Folic Acid	Folic Acid	26	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	26	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	25	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	25	suppressed
Ramipril	Ramipril	25	suppressed
Brilinta	Ticagrelor	24	suppressed
Memantine Hcl Er	Memantine Hcl	24	suppressed
Candesartan-Hydrochlorothiazid	Candesartan/Hydrochlorothiazid	23	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	23	suppressed
Lumigan	Bimatoprost	23	suppressed
Rivastigmine	Rivastigmine Tartrate	23	suppressed
Theophylline Er	Theophylline Anhydrous	23	suppressed
Trueplus Insulin Syringe	Syringe And Needle,insulin,1ml	23	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	22	suppressed
Clonidine Hcl	Clonidine Hcl	22	suppressed
Glyburide	Glyburide	22	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	22	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	22	suppressed
Tobramycin-Dexamethasone	Tobramycin/Dexamethasone	22	19
Amoxicillin	Amoxicillin	21	21
Risperidone	Risperidone	21	suppressed
Allopurinol	Allopurinol	19	suppressed
Glyxambi	Empagliflozin/Linagliptin	19	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	19	suppressed
Primidone	Primidone	19	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	18	suppressed
Lansoprazole	Lansoprazole	18	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	18	18
Propranolol Hcl	Propranolol Hcl	18	suppressed
Synjardy	Empagliflozin/Metformin Hcl	18	suppressed
Clindamycin Hcl	Clindamycin Hcl	17	16
Fluconazole	Fluconazole	17	14
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	17	suppressed
Permethrin	Permethrin	17	15
Silver Sulfadiazine	Silver Sulfadiazine	17	suppressed
Lamotrigine	Lamotrigine	16	suppressed
Bupropion Xl	Bupropion Hcl	15	suppressed
Eletriptan Hbr	Eletriptan Hydrobromide	15	suppressed
Ketoconazole	Ketoconazole	15	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	14	suppressed
Tradjenta	Linagliptin	14	suppressed
Trulicity	Dulaglutide	14	suppressed
Amantadine	Amantadine Hcl	13	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	13	suppressed
Linzess	Linaclotide	13	suppressed
Phenytoin	Phenytoin	13	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	13	suppressed
Alogliptin-Metformin	Alogliptin Benz/Metformin Hcl	12	suppressed
Fluorometholone	Fluorometholone	12	suppressed
Insulin Lispro	Insulin Lispro	12	suppressed
Ivermectin	Ivermectin	12	suppressed
Propafenone Hcl	Propafenone Hcl	12	suppressed
Telmisartan	Telmisartan	12	suppressed
Warfarin Sodium	Warfarin Sodium	12	suppressed
Aripiprazole	Aripiprazole	11	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	11	suppressed
Paroxetine Er	Paroxetine Hcl	11	suppressed
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$100.68 · 2 records	AstraZeneca Pharmaceuticals LP	AIRSUPRA, PAXLOVID	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Paxlovid play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error